Wednesday 19 April 2017

New imaging technique may help some men avoid prostate biopsy


Men who have high levels of prostate-specific antigen (PSA) in their blood face troubling uncertainties. While it’s true that prostate cancer can elevate PSA, so can other conditions, including the benign prostate enlargement that afflicts many men as they get older. PSA levels also vary normally from one man to the next, and some men have unusually high levels even when they’re perfectly healthy. To rule out cancer, doctors might recommend a biopsy. Yet prostate biopsies pose risks of infection, and they can also miss cancer in men who truly have the disease. Most prostate biopsies are guided by transrectal ultrasound, an imaging technology that allows doctors to see the gland while taking tissue samples (called cores) with specialized needles. Tumors may not show up on ultrasound, however, so the biopsy needles might never hit a cancerous target.
A more precise way to investigate elevated PSA results

In January, British researchers reported results from the multi-center PROMIS study showing that a different imaging technology, called multi-parametric magnetic resonance imaging (MP-MRI), could allow some men with high PSA levels to safely avoid a prostate biopsy altogether. “If my MP-MRI was negative, I would not have a biopsy,” said Mark Emberton, M.D., director of the Division of Surgery and Interventional Science at University College London, and a co-author on the study. “And I would do that confidently.”

An MRI machine uses a very large magnet, a radio-wave transmitter, and a computer to construct detailed pictures of structures inside the body. MP-MRI is an advanced form of the technology that allows specially trained radiologists to detect prostate tumors. They can also gauge how aggressive the tumor is by looking at how tightly the cells are packed and how blood and water molecules flow through them.

Tuesday 11 April 2017

Urologic Disease Burden Among Veterans Underestimated


In the Veterans Affairs Healthcare System, estimates of urologic disease prevalence among males and females based only on primary diagnosis will significantly underestimate the true disease burden, say researchers in Los Angeles.
Dr. Jennifer T. Anger of the University of California at Los Angeles and colleagues analyzed reasons for urology-related outpatient visits to VA healthcare facilities in fiscal year 2001. Dr. Anger's team grouped the more than 3.5 million veterans who were seen into four cohorts by primary diagnosis: BPH or lower urinary tract symptoms, UTIs, urinary incontinence, and kidney stones.

According to the report in the July issue of Urology, there were 4,811 veterans with a primary diagnosis of BPH/lower urinary tract symptoms per 100,000, for a prevalence of 4.8%.

The prevalence of UTI was 4,265 per 100,000 female veterans, or 4.3%, and for male veterans, it was 1,719 visits per 100.000, or 1.7%.

The prevalence of urinary incontinence was 2,161 per 100,000 female veterans, or 2.2%, and 515 per 100,000 male veterans, or 0.5%.

The prevalence of kidney stones was 597 per 100,000 veterans, or 0.6%.

Prevalence rates for all four conditions were much higher when secondary diagnoses were included, the Los Angeles team said. "Prevalence estimates based on primary diagnosis, rather than secondary or 'any' diagnosis, significantly underestimated the disease burden among veterans," they write. For example, including patients for whom the urologic condition was not the main reason for their visit raised the prevalence of female UTI from 2.2% to 3.8% and the prevalence of BPH/lower urinary tract symptoms from 4.8% to 11.4%.